On April 22, 2025, Shineco, Inc. reported that its subsidiary, Shineco Life Science, will buy 51% of InfiniClone Limited for $19.9 million in cash and 3.45 million shares of common stock. The transaction has been approved by the board and will be completed within 90 days.